Johnson & Johnson paused the U.S. rollout of its Varipulse heart device after stroke reports. The pause follows four stroke events, affecting patients in the U.S. and Europe.

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.

Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced ...

Johnson & Johnson announced that on January 5, "out of an abundance of caution," Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. Varipulse cases while it ...

Feb 14 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the ...

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.

Johnson & Johnson (NYSE: JNJ) traded lower on Wednesday after the MedTech giant disclosed a temporary pause in U.S. cases treated with its Varipulse Pulsed Field Ablation Platform, which targets ...

Johnson & Johnson restarts limited U.S. release of VARIPULSE™ ...

Johnson & Johnson MedTech has received the US Food and Drug Administration (FDA) approval for its VARIPULSE Platform to treat drug-refractory paroxysmal atrial fibrillation (AFib). This system is ...

Varipulse devices developed by Johnson & Johnson MedTech (NYSE:JNJ) have been approved by the U.S. Food and Drug Administration for treating paroxysmal atrial fibrillation in individuals not ...

Johnson & Johnson said on Wednesday it had temporarily paused the rollout of its Varipulse heart device in the United States, as the company investigates four reported stroke events.